Effect of the new HMG-CoA reductase inhibitor cerivastatin (BAY W 6228) on migration, proliferation and cholesterol synthesis in arterial myocytes

Alberto Corsini, L. Arnaboldi, M. Raiteri, P. Quarato, A. Faggiotto, R. Paoletti, R. Fumagalli

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

The major relation existing between cell growth, migration and cholesterol homeostasis prompted us to investigate the effect of the new 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor cerivastatin (BAY W 6228) on these cellular events. The molecule inhibited in a dose-dependent manner the migration and the replication (evaluated as cell number and nuclear incorporation of 3H-thymidine) of rat arterial SMC with IC50 values of 2.7 μM and 0.5 μM, respectively. Among the tested statins BAY W 6228 resulted to be the most potent inhibitor of cholesterol synthesis and cell proliferation. Conditions producing 80-90% inhibition of cholesterol synthesis correlate with approximately 50% inhibition of cell growth. Similar results were obtained in SMC from human femoral artery. The in vitro inhibition of cell migration and proliferation induced by BAY W 6228 (80% decrease) was completely prevented by the addition of mevalonate and partially prevented (60-80%) by farnesol and geranylgeraniol, confirming the specific role of isoprenoid metabolites-probably through a prenylated protein(s)-in regulating these cellular events. The present results provide evidence that BAY W 6228 interferes, at least in vivo, with smooth muscle cells migration and proliferation, major processes involved in atherogenesis.

Original languageEnglish
Pages (from-to)55-61
Number of pages7
JournalPharmacological Research
Volume33
Issue number1
DOIs
Publication statusPublished - Jan 1996

Fingerprint

Muscle Cells
Oxidoreductases
Cholesterol
Cell Proliferation
Cell Movement
Farnesol
Anticholesteremic Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Mevalonic Acid
Terpenes
Femoral Artery
Growth
Thymidine
Inhibitory Concentration 50
Smooth Muscle Myocytes
Atherosclerosis
Homeostasis
Cell Count
3-hydroxy-3-methylglutaryl-coenzyme A
cerivastatin

Keywords

  • BAY W 6228
  • Cerivastatin
  • Isoprenoids
  • Myocyte migration
  • Myocyte proliferation
  • Statins

ASJC Scopus subject areas

  • Pharmacology

Cite this

Effect of the new HMG-CoA reductase inhibitor cerivastatin (BAY W 6228) on migration, proliferation and cholesterol synthesis in arterial myocytes. / Corsini, Alberto; Arnaboldi, L.; Raiteri, M.; Quarato, P.; Faggiotto, A.; Paoletti, R.; Fumagalli, R.

In: Pharmacological Research, Vol. 33, No. 1, 01.1996, p. 55-61.

Research output: Contribution to journalArticle

Corsini, Alberto ; Arnaboldi, L. ; Raiteri, M. ; Quarato, P. ; Faggiotto, A. ; Paoletti, R. ; Fumagalli, R. / Effect of the new HMG-CoA reductase inhibitor cerivastatin (BAY W 6228) on migration, proliferation and cholesterol synthesis in arterial myocytes. In: Pharmacological Research. 1996 ; Vol. 33, No. 1. pp. 55-61.
@article{e59141613639414b93e6c3b5fb41f972,
title = "Effect of the new HMG-CoA reductase inhibitor cerivastatin (BAY W 6228) on migration, proliferation and cholesterol synthesis in arterial myocytes",
abstract = "The major relation existing between cell growth, migration and cholesterol homeostasis prompted us to investigate the effect of the new 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor cerivastatin (BAY W 6228) on these cellular events. The molecule inhibited in a dose-dependent manner the migration and the replication (evaluated as cell number and nuclear incorporation of 3H-thymidine) of rat arterial SMC with IC50 values of 2.7 μM and 0.5 μM, respectively. Among the tested statins BAY W 6228 resulted to be the most potent inhibitor of cholesterol synthesis and cell proliferation. Conditions producing 80-90{\%} inhibition of cholesterol synthesis correlate with approximately 50{\%} inhibition of cell growth. Similar results were obtained in SMC from human femoral artery. The in vitro inhibition of cell migration and proliferation induced by BAY W 6228 (80{\%} decrease) was completely prevented by the addition of mevalonate and partially prevented (60-80{\%}) by farnesol and geranylgeraniol, confirming the specific role of isoprenoid metabolites-probably through a prenylated protein(s)-in regulating these cellular events. The present results provide evidence that BAY W 6228 interferes, at least in vivo, with smooth muscle cells migration and proliferation, major processes involved in atherogenesis.",
keywords = "BAY W 6228, Cerivastatin, Isoprenoids, Myocyte migration, Myocyte proliferation, Statins",
author = "Alberto Corsini and L. Arnaboldi and M. Raiteri and P. Quarato and A. Faggiotto and R. Paoletti and R. Fumagalli",
year = "1996",
month = "1",
doi = "10.1006/phrs.1996.0009",
language = "English",
volume = "33",
pages = "55--61",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press",
number = "1",

}

TY - JOUR

T1 - Effect of the new HMG-CoA reductase inhibitor cerivastatin (BAY W 6228) on migration, proliferation and cholesterol synthesis in arterial myocytes

AU - Corsini, Alberto

AU - Arnaboldi, L.

AU - Raiteri, M.

AU - Quarato, P.

AU - Faggiotto, A.

AU - Paoletti, R.

AU - Fumagalli, R.

PY - 1996/1

Y1 - 1996/1

N2 - The major relation existing between cell growth, migration and cholesterol homeostasis prompted us to investigate the effect of the new 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor cerivastatin (BAY W 6228) on these cellular events. The molecule inhibited in a dose-dependent manner the migration and the replication (evaluated as cell number and nuclear incorporation of 3H-thymidine) of rat arterial SMC with IC50 values of 2.7 μM and 0.5 μM, respectively. Among the tested statins BAY W 6228 resulted to be the most potent inhibitor of cholesterol synthesis and cell proliferation. Conditions producing 80-90% inhibition of cholesterol synthesis correlate with approximately 50% inhibition of cell growth. Similar results were obtained in SMC from human femoral artery. The in vitro inhibition of cell migration and proliferation induced by BAY W 6228 (80% decrease) was completely prevented by the addition of mevalonate and partially prevented (60-80%) by farnesol and geranylgeraniol, confirming the specific role of isoprenoid metabolites-probably through a prenylated protein(s)-in regulating these cellular events. The present results provide evidence that BAY W 6228 interferes, at least in vivo, with smooth muscle cells migration and proliferation, major processes involved in atherogenesis.

AB - The major relation existing between cell growth, migration and cholesterol homeostasis prompted us to investigate the effect of the new 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor cerivastatin (BAY W 6228) on these cellular events. The molecule inhibited in a dose-dependent manner the migration and the replication (evaluated as cell number and nuclear incorporation of 3H-thymidine) of rat arterial SMC with IC50 values of 2.7 μM and 0.5 μM, respectively. Among the tested statins BAY W 6228 resulted to be the most potent inhibitor of cholesterol synthesis and cell proliferation. Conditions producing 80-90% inhibition of cholesterol synthesis correlate with approximately 50% inhibition of cell growth. Similar results were obtained in SMC from human femoral artery. The in vitro inhibition of cell migration and proliferation induced by BAY W 6228 (80% decrease) was completely prevented by the addition of mevalonate and partially prevented (60-80%) by farnesol and geranylgeraniol, confirming the specific role of isoprenoid metabolites-probably through a prenylated protein(s)-in regulating these cellular events. The present results provide evidence that BAY W 6228 interferes, at least in vivo, with smooth muscle cells migration and proliferation, major processes involved in atherogenesis.

KW - BAY W 6228

KW - Cerivastatin

KW - Isoprenoids

KW - Myocyte migration

KW - Myocyte proliferation

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=0029980255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029980255&partnerID=8YFLogxK

U2 - 10.1006/phrs.1996.0009

DO - 10.1006/phrs.1996.0009

M3 - Article

C2 - 8817647

AN - SCOPUS:0029980255

VL - 33

SP - 55

EP - 61

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

IS - 1

ER -